Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor
Authors:
- On Behalf Of The Société Francophone de Greffe de Moelle Et de Thérapie Cellulaire (Sfgm-Tc)O(On Behalf Of The Société Francophone de Greffe de Moelle Et de Thérapie Cellulaire (Sfgm-Tc)
- 29 October 2019
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (4) , 749-757
Abstract
Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for acute myeloid leukemia. In the absence of an HLA-matched related or unrelated donor (MRD or MUD), the best alternative donor source remains controversial. Umbilical cord blood and haploidentical donors offer a shorter delay from indication to transplantation. This retrospective multicentre study of a French registry compares overall survival in the 18 months following registration in the absence of a MRD between four types of donors. Between 2012 and 2016, 1302 patients were transplanted using MUD (control, n = 803), mismatched MUD (n = 219), umbilical cord blood (n = 153) and haploidentical (n = 127) donors. Multivariate analyses were conducted for overall survival after registration, after transplant, and transplant-related mortality. After adjustment for variables, the type of donor did not influence any of the three end points. Our results confirmed the significant negative impact of longer time between registration and transplant: HR = 1.04 [1.02–1.06] (p < 0.0001). This indicates a positive correlation between better survival and shorter registration-to-transplantation wait time. In the absence of a sibling donor, the alternative stem cell source does not impact early survival in acute myeloid leukemia patients. The minimization of registration-to-transplantation time should be considered when weighing the alternative donor options.Keywords
This publication has 18 references indexed in Scilit:
- Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1Blood Advances, 2017
- How to select the best available related or unrelated donor of hematopoietic stem cells?Haematologica, 2016
- Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemiaBlood, 2015
- Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemiaLeukemia, 2015
- Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplantsBone Marrow Transplantation, 2015
- Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling GraftsTransplantation and Cellular Therapy, 2014
- HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. RegistryNew England Journal of Medicine, 2014
- Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemiaBlood, 2012
- Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98AJournal of Clinical Oncology, 2010
- Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen–Identical Siblings Versus Human Leukocyte Antigen–Allelic–Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell TherapyJournal of Clinical Oncology, 2006